GOBLET: A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab

Arnold, Dirk et al, Previously presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022